Common Sense for the Biochemist

Our long term strategy is to focus on protein-based pharmaceuticals where we believe the benefits of the Stratosome™ Biologics System and the Affinity Capture System give us a market advantage through flexibility and scalability of production, by enabling the production of proteins that are problematic using other transgenic systems, through lower capital costs for protein production and purification facilities and lower production costs. Initially we have chosen to focus on products where clinical efficacy has already been demonstrated, such as insulin, or where early clinical data is encouraging, such as Apo AI. For such product candidates, the key technical challenges are primarily those associated with the deployment of our technology towards the production of the target protein. As the first products move through the development pipeline, we expect to develop additional product candidates. As a complement to this long term strategy, we are developing non-pharmaceutical products, which have the benefits of lower regulatory hurdles, development costs and capital requirements, allowing us to generate revenues in the short to medium term with relatively low risk. In addition, commercialization of non-pharmaceutical products will allow us to continue developing the organizational infrastructure required to develop and commercialize protein-based pharmaceuticals.

# posted by Brian @ 1/01/2005 07:21:00 PM

«Medicines of the future will rely on biotechnology. It is essential to produce cost-effective pharmaceuticals without compromising quality and security in order to meet the demands of the public. It is the goal of MERISTEM Therapeutics to further advance therapeutic technology through the production of proteins in plants to provide lower cost pharmaceuticals.»

# posted by Brian @ 1/01/2005 07:17:00 PM

Large Scale Biology Corporation's (LSBC) goal is to develop, manufacture and commercialize plant-made pharmaceutical proteins and vaccines. LSBC has successfully garnered an international reputation as an innovator in biomanufacturing. Driven by its unique GENEWARE® RNA plant viral gene expression technology, LSBC has taken integration of plant-made pharmaceuticals from gene to production further than any other company. GENEWARE® technology is complemented by a full commercial-scale capability to produce, extract, purify, finish and fill a wide range of pharmaceutical proteins.

- From Large Scale Biology's Website Website News items: LSBC/Growers Research Group Collaboration: 11/22/05 - Growers Research Group and LSBC ink licensing deal LSBC/Cincinatti Children's Hospital alliance: Blogged here
8/1/05 - Press Release - Large Scale Biology Corporation Receives U.S. Food and Drug Administration's Orphan Drug Designation for Its Lysosomal Acid Lipase Product
5/2/05 - Press Release - Large Scale Biology Corporation and Cincinnati Children's Accelerate Lysosomal Acid Lipase Development Program LSBC/Planet Biotechnology alliance: Blogged here 7/12/05 - Press Release - Yahoo - Large Scale Biology Corporation and Planet Biotechnology Inc. Announce Expansion of Biomanufacturing Program Financial News: 12/22/05 - LSBC Ceases Operations 12/12/05 - LSBC announces 1 for 5 stock split 10/30/05 - LSBC Firms Up Funding 10/9/05 - LSBC Backs Out of Equity Deal? 8/9/05 - Press Release - Large Scale Biology Corporation (LSBC) Reports Financial Results for Second Quarter 2005 8/8/05 - Press Release - Large Scale Biology Corporation Secures Equity Line of Credit up to $15,000,000 From Southridge Capital Management LLC's Advised Fund, Brittany Capital Management Ltd. and Bridge Financing from CEO and Chairman 8/3/05 - Audio - Wall Street Reporter interview with Chairman of the Board Bob Irwin 8/2/05 - Press Release - Large Scale Biology to Transfer Listing of Securities from Nasdaq National Market to Nasdaq SmallCap Market Patents #6344597 - Interspecific nicotiana hybrids and their progeny RJR Reynolds documents Please note: These documents were released as part of the Master Settlement Agreement between the various big tobacco corporations and the U.S. Government. Letter from Bob Erwin to Robert DiMarco expressing interest in a business relationship
Notes from Gary Hellman to Robert DiMarco on Biosource Biosource/RJR Business Contract Another memo from Gary Hellman to Robert DiMarco regarding the proposed collaboration 1991 Biosource field trials report

# posted by Brian @ 1/01/2005 03:44:00 PM